Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 2/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL356683 | 1.00 | CYP3A4 (0.42) | CYP3A4TDP1ESR1ESR2KDM4E | |
| SCHEMBL4619337 | 0.98 | CYP3A4 (0.41) | CYP3A4TDP1ESR1ESR2KDM4E | |
| SCHEMBL16180769 | 0.98 | CYP3A4 (0.41) | CYP3A4TDP1ESR1ESR2KDM4E | |
| SCHEMBL5330004 | 0.90 | ESR1 (0.36) | CYP3A4TDP1ESR1ESR2 | |
| SCHEMBL4744273 | 0.86 | CYP3A4 (0.31) | CYP3A4TDP1 | |
| SCHEMBL1443600 | 0.85 | CYP2A6 (0.35) | TDP1 | |
| SCHEMBL900597 | 0.82 | — | — | |
| SCHEMBL1460886 | 0.82 | CYP2A6 (0.35) | CYP3A4TDP1 | |
| SCHEMBL3632076 | 0.81 | HSD17B2 (0.33) | — | |
| SCHEMBL8913546 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 998 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12091395-B2 | Griseofulvin compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-09-17 | — | — | US | claimed |
| WO-2024151992-A1 | PREPARATION OF A TYK2 INHIBITOR | VENTYX BIOSCIENCES, INC. (US) | 2024-07-18 | — | — | WO | claimed |
| US-20240150309-A1 | GRISEOFULVIN COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-05-09 | — | — | US | claimed |
| EP-4132902-A1 | PD-CATALYZED AMINATION OF FLUORINATED ARYL CHLORIDES | BASF SE (DE) | 2023-02-15 | — | — | EP | claimed |
| EP-2482978-B1 | HETEROGENEOUS RHODIUM METAL CATALYSTS | UNIV ALBERTA (CA) | 2018-05-09 | — | — | EP | claimed |
| WO-2012173572-A1 | STEREOSELECTIVE SYNTHESIS OF HIGHLY SUBSTITUTED ENAMIDES | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2012-12-20 | — | — | WO | claimed |
| EP-2482978-A1 | HETEROGENEOUS RHODIUM METAL CATALYSTS | The Governors Of The University Of Alberta (CA) | 2012-08-08 | — | — | EP | claimed |
| WO-2011035445-A1 | HETEROGENEOUS RHODIUM METAL CATALYSTS | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2011-03-31 | — | — | WO | claimed |
| EP-2203438-A1 | CYANOISOQUINOLINE | H. Lundbeck A/S (DK) | 2010-07-07 | — | — | EP | claimed |
| EP-2134710-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | Intra-Cellular Therapies, Inc. (US) | 2009-12-23 | — | — | EP | claimed |
| EP-1799652-A1 | N-BENZENESULFONYL SUBSTITUTED ANILINO-PYRIMIDINE ANALOGS | Wyeth (US) | 2007-06-27 | — | — | EP | claimed |
| WO-2007045593-A2 | NAPHTHYL DERIVATIVES AS INHIBITORS OF BETA-AMYLOID AGGREGATION | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2007-04-26 | — | — | WO | claimed |
| WO-2007025693-A1 | PROCESS FOR THE PRODUCTION OF ANILINES | SYNGENTA PARTICIPATIONS AG (CH) | 2007-03-08 | — | — | WO | claimed |
| EP-1730123-A1 | NOVEL AMINATION PROCESS | AstraZeneca AB (SE) | 2006-12-13 | — | — | EP | claimed |
| WO-2006044457-A1 | N-BENZENESULFONYL SUBSTITUTED ANILINO-PYRIMIDINE ANALOGS | WYETH (US) | 2006-04-27 | — | — | WO | claimed |
| WO-2005108338-A1 | NOVEL THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER, METABOLIC DISEASES AND SKIN DISORDERS | AUSPEX PHARMACEUTICALS (US) | 2005-11-17 | — | — | WO | claimed |
| WO-2005090318-A1 | NOVEL AMINATION PROCESS | ASTRAZENECA AB (SE) | 2005-09-29 | — | — | WO | claimed |
| EP-1100774-A1 | IMPROVED ARYLAMINE SYNTHESIS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2001-05-23 | — | — | EP | claimed |
| WO-2000005199-A1 | IMPROVED ARYLAMINE SYNTHESIS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2000-02-03 | — | — | WO | claimed |
| WO-1995008526-A1 | HYDROGENATION | PFIZER RESEARCH AND DEVELOPMENT COMPANY, N.V./S.A. (IE) | 1995-03-30 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150309-A1 | GRISEOFULVIN COMPOUND | PTGS1, CYP11B1, GRIA1 | CYP3A4 333/4885TDP1 4416/4885ESR1 1192/4885 |
| US-12091395-B2 | Griseofulvin compound | PTGS1, CYP11B1, GRIA1 | CYP3A4 333/4885TDP1 4416/4885ESR1 1192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.